Methodology of the BIOPACT RCT, a multi-center, randomized, non-inferiority trial evaluating safety and efficacy of Passeo-18 Lux Drug-Coated Balloon (DCB) of Biotronik compared to the Medtronic IN.PACT Admiral DCB in the treatment of subjects with lesions of the femoropopliteal artery

Autor: Koen Deloose, Wouter Lansink, Marianne Brodmann, Martin Werner, Koen Keirse, Yann Gouëffic, Jürgen Verbist, Lieven Maene, Jeroen Hendriks, Jerome Brunet, Eric Ducasse, Kara Levent, Antoine Sauguet, Sébastien Déglise, Femke Vandael
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Cardiovascular and interventional radiology
ISSN: 0174-1551
Popis: Although effectiveness and safety of many different paclitaxel coated balloons in the treatment of peripheral arterial disease (PAD) are extensively studied, there is a lack of direct head-to-head comparison studies. To meet this need and to avoid potential "class-effects", the BIOPACT was set up. The purpose is to demonstrate the safety and efficacy of the Passeo-18 Lux DCB (Biotronik) for treatment of patients with symptomatic PAD due to femoropopliteal lesions.302 patients are randomized in a 1:1 manner to treatment with either the Passeo-18 Lux DCB or the IN.PACT Admiral DCB (Medtronic) for testing of a formal non-inferiority hypothesis. The participants will be followed for 5 years. The primary efficacy endpoint is freedom from clinically-driven target lesion revascularization (CD-TLR) at 12 months, defined as any re-intervention at the target lesion due to symptoms, drop of ankle brachial index (ABI) 20% or 0.15 compared to post-procedural ABI. Primary safety endpoint is a composite of freedom from device/procedure-related death through 30 days post-index procedure, freedom from major target limb amputation and clinically-driven target vessel revascularization (CD-TVR) through 12 months post-index procedure. Secondary endpoints can be found at clinicaltrials.gov, ID NCT03884257.As full enrolment was reached by the beginning of September, the investigators expect complete analysis of the primary endpoints by the end of 2022; Meanwhile preliminary results will be disclosed during 2022. As in terms of randomized head-to-head efficacy and safety analysis, this study on paclitaxel coated balloons may provide additional information to clinicians and healthcare providers. Trial registration ClinicalTrials.gov ID: NCT03884257 LEVEL OF EVIDENCE: Level 2, Randomized trial.
Databáze: OpenAIRE
Externí odkaz: